ABUS · Arbutus Biopharma Corporation Common Stock
View on chartInsiders & Stakes
| Roivant Sciences Ltd. 10% Owner | ▼ Sell | Other | 29,880,079 Shares held | 10/1/2026 | View profile |
| Michael J. McElhaugh Chief Business Officer | ▲ Buy | Grant | 1,658,003 Shares held | 2/14/2025 | View profile |
| Michael J. Sofia Chief Scientific Officer | ▼ Sell | Open Market | 1,485,121 Shares held | 2/2/2024 | View profile |
| David C. Hastings Director | ▲ Buy | Grant | 249,824 Shares held | 2/14/2025 | View profile |
| Collier William H. President and CEO | ▲ Buy | Grant | 216,500 Shares held | 2/1/2023 | View profile |
| Karen Sims Chief Medical Officer | ▲ Buy | Grant | 155,494 Shares held | 2/14/2025 | View profile |
| J. Christopher Naftzger General Counsel and CCO | ▲ Buy | Grant | 140,544 Shares held | 2/14/2025 | View profile |
| Tuan Nguyen Chief Financial Officer | ▼ Sell | Other | 111,882 Shares held | 10/1/2026 | View profile |
| Howard Elizabeth EVP, GC, Compliance | ▲ Buy | Grant | 86,024 Shares held | 2/1/2023 | View profile |
| Lindsay Androski President and CEO | ▼ Sell | Other | 47,682 Shares held | 10/1/2026 | View profile |
| Keith S. Manchester Director | ▼ Sell | Open Market | 46,069 Shares held | 8/14/2024 | View profile |
| Beardsley Robert A Director | ▼ Sell | Other | 14,328 Shares held | 10/1/2026 | View profile |
| Sawhney Roger Director | ▼ Sell | Other | 13,683 Shares held | 10/1/2026 | View profile |
Transaction History
| Beardsley Robert A | ▼ Sell | Other | 17,948 | $90K | 10/1/2026 |
| Tuan Nguyen | ▼ Sell | Other | 48,081 | $240K | 10/1/2026 |
| Sawhney Roger | ▼ Sell | Other | 17,142 | $86K | 10/1/2026 |
| Lindsay Androski | ▼ Sell | Other | 24,655 | $123K | 10/1/2026 |
| Roivant Sciences Ltd. | ▼ Sell | Other | 8,967,383 | $44.8M | 10/1/2026 |
| Lindsay Androski | ▲ Buy | Option Exercise | 116,408 | $373K | 9/18/2026 |
| Lindsay Androski | ▲ Buy | Option Exercise | 10,456 | $46K | 9/18/2026 |
| Lindsay Androski | ▼ Sell | Tax Withholding | 82,527 | $418K | 9/18/2026 |
| Tuan Nguyen | ▲ Buy | Option Exercise | 265,625 | $927K | 9/18/2026 |
| Tuan Nguyen | ▲ Buy | Option Exercise | 27,475 | $121K | 9/18/2026 |
| Tuan Nguyen | ▼ Sell | Tax Withholding | 206,637 | $1.0M | 9/18/2026 |
| Sawhney Roger | ▲ Buy | Option Exercise | 52,533 | $175K | 9/18/2026 |
| Sawhney Roger | ▲ Buy | Option Exercise | 78,800 | $334K | 9/18/2026 |
| Sawhney Roger | ▼ Sell | Tax Withholding | 100,508 | $510K | 9/18/2026 |
| Beardsley Robert A | ▲ Buy | Option Exercise | 52,533 | $168K | 9/18/2026 |
| Beardsley Robert A | ▲ Buy | Option Exercise | 78,800 | $334K | 9/18/2026 |
| Beardsley Robert A | ▼ Sell | Tax Withholding | 99,057 | $502K | 9/18/2026 |
| Tuan Nguyen | ▲ Buy | Grant | 73,500 | $0 | 2/2/2026 |
| Lindsay Androski | ▲ Buy | Grant | 28,000 | $0 | 2/2/2026 |
| Michael J. McElhaugh | ▲ Buy | Grant | 177,000 | $0 | 2/14/2025 |
| David C. Hastings | ▲ Buy | Grant | 90,100 | $0 | 2/14/2025 |
| Karen Sims | ▲ Buy | Grant | 49,300 | $0 | 2/14/2025 |
| J. Christopher Naftzger | ▲ Buy | Grant | 54,300 | $0 | 2/14/2025 |
| David C. Hastings | ▼ Sell | Open Market | 22,183 | $73K | 2/4/2025 |
| Karen Sims | ▼ Sell | Open Market | 19,348 | $64K | 2/4/2025 |
| Michael J. McElhaugh | ▼ Sell | Open Market | 23,790 | $78K | 2/4/2025 |
| J. Christopher Naftzger | ▼ Sell | Open Market | 11,333 | $37K | 2/4/2025 |
| Keith S. Manchester | ▲ Buy | Option Exercise | 54,915 | $31K | 8/14/2024 |
| Keith S. Manchester | ▼ Sell | Open Market | 8,846 | $33K | 8/14/2024 |
| Karen Sims | ▼ Sell | Open Market | 4,358 | $10K | 2/2/2024 |
| David C. Hastings | ▼ Sell | Open Market | 9,593 | $22K | 2/2/2024 |
| Michael J. Sofia | ▼ Sell | Open Market | 9,982 | $23K | 2/2/2024 |
| Michael J. McElhaugh | ▼ Sell | Open Market | 10,164 | $24K | 2/2/2024 |
| J. Christopher Naftzger | ▲ Buy | Grant | 95,100 | $0 | 2/1/2024 |
| Karen Sims | ▲ Buy | Grant | 101,000 | $0 | 2/1/2024 |
| David C. Hastings | ▲ Buy | Grant | 112,500 | $0 | 2/1/2024 |
| Michael J. Sofia | ▲ Buy | Grant | 109,500 | $0 | 2/1/2024 |
| Michael J. McElhaugh | ▲ Buy | Grant | 123,800 | $0 | 2/1/2024 |
| Michael J. McElhaugh | ▲ Buy | Grant | 83,700 | $0 | 2/1/2023 |
| David C. Hastings | ▲ Buy | Grant | 79,000 | $0 | 2/1/2023 |
| Michael J. Sofia | ▲ Buy | Grant | 82,200 | $0 | 2/1/2023 |
| Howard Elizabeth | ▲ Buy | Grant | 69,700 | $0 | 2/1/2023 |
| Collier William H. | ▲ Buy | Grant | 216,500 | $0 | 2/1/2023 |
| Michael J. Sofia | ▼ Sell | Open Market | 200,000 | $1.0M | 12/1/2021 |
| Roivant Sciences Ltd. | ▼ Sell | Other | 22,833,922 | — | 10/18/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
ABUS Featured in Whale Alert List of 10 Health Care Stocks
Arbutus Biopharma (ABUS) was named in a Benzinga article that highlighted 10 health care stocks receiving whale alerts during the day. The mention suggests that large institutional traders have placed sizable orders in ABUS. The stock is currently near its $4.26 support level, with an RSI of 40.4 and recent volume spikes. This activity may signal increased market interest in ABUS.
ABUS Featured in Whale Alert List of 10 Health Care Stocks. Arbutus Biopharma (ABUS) was named in a Benzinga article that highlighted 10 health care stocks receiving whale alerts during the day. The mention suggests that large institutional traders have placed sizable orders in ABUS. The stock is currently near its $4.26 support level, with an RSI of 40.4 and recent volume spikes. This activity may signal increased market interest in ABUS.